Abstract
[123I]TPCNE (1(trans-[123I]iodopropen-2-yl)-4-[(4- cyanophenoxy)methyl] piperidine; Ki = 0.67 nM; log P = 3.36) is a novel sigma-1 receptor SPET ligand. In this study, we developed an optimized labeling method for [123I]TPCNE and investigated the kinetics, binding characteristics, and whole-body distribution of this tracer for the first time in humans. We also performed a challenge with the sigma-1 receptor antagonist haloperidol against [123I]TPCNE. Seven healthy volunteers were recruited. Dynamic brain SPET scans were performed following i.v. administration of 185 MBq [123I]TPCNE in all seven subjects. Three of the subjects were given oral haloperidol (2.5 mg) ∼1 h before the scan. The dynamic data were analyzed with both reversible and irreversible compartmental models. [123I]TPCNE showed high uptake in brain and liver. All non-haloperidol-treated subjects showed a high whole-brain uptake (average: 8.7% of injected activity). No significant clearance of the tracer was seen up to 30 h post injection. In the haloperidol-treated subjects, the time-activity curves clearly demonstrated clearance of the tracer from the brain. Regional radioactivity concentrations were reduced by haloperidol from 42% in the cerebellum to 73% in the thalamus. [123I]TPCNE demonstrated high brain uptake, with highest binding found in the posterior cingulate. A region in which binding was unaffected by haloperidol pretreatment could not be identified, and the time-activity data were best described by an irreversible model.
Original language | English |
---|---|
Pages (from-to) | 109-117 |
Number of pages | 9 |
Journal | Synapse |
Volume | 60 |
Issue number | 2 |
DOIs | |
Publication status | Published - 19 May 2006 |
Keywords
- Antipsychotic drugs
- Brain
- Schizophrenia
- Sigma-1 receptors
- SPET